Analysts' recommendations: Gamida Cell Ltd.

30/24/30	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
15/23/15	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/23/15	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/23/19	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/23/16	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases: Gamida Cell Ltd.

27/24/27	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/24/27	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/24/22	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
23/24/23	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/24/29	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors: Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	01/06/2021
Rory Nealon COO	Chief Operating Officer	59	24/05/2024

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	01/04/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets 10:24:51 24/05/2024 pm IST			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	26.18L 23.36L 21.76L 19.8L 37.29L 25Cr 37.57L 2.63Cr 1.02Cr 13Cr 98.29L 96.17L 41Cr	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	3.9Cr 3.48Cr 3.24Cr 2.95Cr 5.56Cr 375.67Cr 5.6Cr 39Cr 15Cr 191.73Cr 15Cr 14Cr 616.3Cr	EV / Sales 2022	-	EV / Sales 2023	5,10,81,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

27/25/27	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/24/22	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/24/18	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/24/18	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/24/18	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
18/24/18	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
24/24/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/24/10	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
05/24/05	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
28/24/28	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/24/28	Top Premarket Decliners	MT
27/24/27	Top Midday Decliners	MT
27/24/27	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

3 years	0.01	1.05
5 years	0.01	4.72
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/01/24	Ronit Simantov	Free	Chief Technology Officer	4,80,319	0.3621%
31/01/24	Ivan Borrello	Free	Director	2,00,000	0.1508%
31/01/24	Kenneth Moch	Free	Director	2,00,000	0.1508%

Gamida Cell Ltd. Share Price

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation: Gamida Cell Ltd.

Latest news: Gamida Cell Ltd.

Analysts' recommendations: Gamida Cell Ltd.

Press Releases: Gamida Cell Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.22%	26.19L
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	7.42TCr
ARGENX SE	-0.37%	-3.88%	+19.75%	+78.35%	5.74TCr
LONZA GROUP AG	+1.63%	+0.98%	+3.83%	+38.21%	4.76TCr
REVOLUTION MEDICINES, INC.	+0.50%	+1.32%	+344.62%	+753.25%	4.43TCr
IQVIA HOLDINGS INC.	+3.05%	-1.58%	+28.78%	+35.46%	4.25TCr
BEONE MEDICINES AG	+1.00%	+0.22%	+5.17%	+113.80%	4.07TCr
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	3.1TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+4.53%	+31.34%	+26.92%	2.85TCr
BIONTECH SE	+0.76%	-0.89%	-7.44%	-11.43%	2.43TCr
Average	+1.39%	-0.16%	+48.47%	+108.46%	3.91TCr
Weighted average by Cap.	+1.52%	-0.84%	+58.06%	+140.75%

	2022	2023
Net sales	-	1.78 1.59 1.48 1.35 2.54 171.81 2.56 17.92 6.97 87.69 6.7 6.55 281.87
Net income	-7.94Cr -7.08Cr -6.6Cr -6Cr -11Cr -764.44Cr -11Cr -80Cr -31Cr -390.16Cr -30Cr -29Cr -1.25TCr	-6.3Cr -5.62Cr -5.24Cr -4.76Cr -8.97Cr -606.7Cr -9.04Cr -63Cr -25Cr -309.65Cr -24Cr -23Cr -995.32Cr
Net Debt	3.93Cr 3.51Cr 3.27Cr 2.97Cr 5.6Cr 378.56Cr 5.64Cr 39Cr 15Cr 193.21Cr 15Cr 14Cr 621.05Cr	3.64Cr 3.25Cr 3.02Cr 2.75Cr 5.18Cr 350.45Cr 5.22Cr 37Cr 14Cr 178.87Cr 14Cr 13Cr 574.94Cr